STOK Stoke Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 10 May 2022 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

   – 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in Phase 1/2a clinical studies MONARCH, ADMIRAL, and SWALLOWTAIL –

   – Recent preclinical data support ongoing development of STK-002 as the first potential disease-modifying approach for the treatment of Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder –

   – As of March 31, 2022, Company had $293.8 million in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fund operations into 2025 –

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with…

   View Full Article
2. 02 May 2022 Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

   – Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company's work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy (ADOA) –

   – ADOA is the most common inherited optic nerve disorder –

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein…

   View Full Article
3. 07 April 2022 Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

   – New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA) –

   – ADOA is the most common inherited optic nerve disorder –

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting being held May 1-4, 2022 in Denver, Colorado. STK-002 is a proprietary antisense oligonucleotide (ASO) in preclinical development for the treatment of autosomal dominant optic atrophy (ADOA).

   The…

   View Full Article
4. 05 April 2022 Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m. ET.

   A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/, or by clicking here. A replay of the webcast will be available for 90 days following the event.

   About Stoke Therapeutics
   Stoke Therapeutics (NASDAQ:STOK), is a biotechnology company dedicated to addressing the underlying…

   View Full Article
5. 10 March 2022 Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

   – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome –

   – Company remains on track to provide additional clinical data in 2H 2022 from patients treated with multiple ascending doses of STK-001 at 30mg –

   – Preclinical toxicology studies underway for STK-002, the first potential disease-modifying approach for the treatment of Autosomal Dominant Optic Atrophy (ADOA) –

   – As of December 31, 2021, Company had $220.4 million in cash, cash equivalents, marketable securities, and restricted cash –

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with…

   View Full Article